GlassScriptPhysician profile
Xiaoming Hong
NPI 1881626638
$2,792.33
in general payments reported to CMS, 2019-2025
25 companies · $67.53 in 2025
The $67.53 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $274 · 2021: $12.09 · 2023: $194 · 2024: $532 · 2025: $67.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.23 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $291.50 | 2019-2024 | |
| Lilly USA, LLC | $222.95 | 2019-2020 | |
| Allergan, INC. | $204.01 | 2019 | |
| Abbvie INC. | $186.79 | 2023-2025 | |
| Amarin Pharma, INC. | $166.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $163.02 | 2019-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.35 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $149.78 | 2019-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $139.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $124.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $114.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $96.98 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $83.26 | 2019-2020 | |
| Exact Sciences Corporation | $58.71 | 2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.74 | 2019 | |
| Phathom Pharmaceuticals, INC. | $40.54 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $39.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.26 | 2024 | Soliris |
| Abbott Laboratories | $23.44 | 2020 | |
| Paratek Pharmaceuticals, INC. | $23.43 | 2024 | Nuzyra |
| Dexcom, INC. | $19.86 | 2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $13.09 | 2019 | |
| Eisai INC. | $12.09 | 2021 | |
| Hikma Pharmaceuticals USA | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoming Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.